ArticleNature communications2014
A smart and versatile theranostic nanomedicine platform based on nanoporphyrin.
Article in Nature communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
131 citing papers in PubMed.
- Catechin-Targeted Nano-Enhanced Colorimetric Sensor Array Based on Quantum Dots-Nano Porphyrin for Precise Analysis of Xihu Longjing from Adjacent Origins.Foods (Basel, Switzerland) · 2025Article
- In situ radiochemical doping of functionalized inorganic nanoplatforms for theranostic applications: a paradigm shift in nanooncology.Journal of nanobiotechnology · 2025Review
- Imaging-guided precision hyperthermia with magnetic nanoparticles.Nature reviews bioengineering · 2025Article
- Recent Advancement in MRI-Based Nanotheranostic Agents for Tumor Diagnosis and Therapy Integration.International journal of nanomedicine · 2025Review
- Exploring innovative strides in radiolabeled nanoparticle progress for multimodality cancer imaging and theranostic applications.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
- Review
- Emergence and impact of theranostic-nanoformulation of triple therapeutics for combination cancer therapy.Smart medicine · 2024Review
- A Novel Approach for Bladder Cancer Treatment: Nanoparticles as a Drug Delivery System.International journal of nanomedicine · 2024Review
- Recent Advances in Targeted Therapies for Infantile Hemangiomas.International journal of nanomedicine · 2024Review
- ROS-generating nanoplatforms as selective and tunable therapeutic weapons against cancer.Discover nano · 2023Review
- Review
- Visible Laser Light Mediated Cancer Therapy via Photothermal Effect of Tannin-Stabilized Magnetic Iron Oxide Nanoparticles.Nanomaterials (Basel, Switzerland) · 2023Article
- Recent Advances in Supramolecular-Macrocycle-Based Nanomaterials in Cancer Treatment.Molecules (Basel, Switzerland) · 2023Review
- Role of traditional Chinese medicine monomers in cerebral ischemia/reperfusion injury:a review of the mechanism.Frontiers in pharmacology · 2023Review
- Radiolabeled nanomaterial for cancer diagnostics and therapeutics: principles and concepts.Cancer nanotechnology · 2023Review
- Polymeric dual-modal imaging nanoprobe with two-photon aggregation-induced emission for fluorescence imaging and gadolinium-chelation for magnetic resonance imaging.Bioactive materials · 2023Article
- Stimuli-responsive crosslinked nanomedicine for cancer treatment.Exploration (Beijing, China) · 2022Review
- Phototherapy with Cancer-Specific Nanoporphyrin Potentiates Immunotherapy in Bladder Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Synthetic biology-instructed transdermal microneedle patch for traceable photodynamic therapy.Nature communications · 2022Article
- NIR-II AIEgens with Photodynamic Effect for Advanced Theranostics.Molecules (Basel, Switzerland) · 2022Review
71 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Multifunctional nanoparticles with combined diagnostic and therapeutic functions show great promise towards personalized nanomedicine. However, attaining consistently high performance of these functions in vivo in one single nanoconstruct remains extremely challenging. Here we demonstrate the use of one single polymer to develop a smart 'all-in-one' nanoporphyrin platform that conveniently integrates a broad range of clinically relevant functions. Nanoporphyrins can be used as amplifiable multimodality nanoprobes for near-infrared fluorescence imaging (NIRFI), magnetic resonance imaging (MRI), positron emission tomography (PET) and dual modal PET-MRI. Nanoporphyrins greatly increase the imaging sensitivity for tumour detection through background suppression in blood, as well as preferential accumulation and signal amplification in tumours. Nanoporphyrins also function as multiphase nanotransducers that can efficiently convert light to heat inside tumours for photothermal therapy (PTT), and light to singlet oxygen for photodynamic therapy (PDT). Furthermore, nanoporphyrins act as programmable releasing nanocarriers for targeted delivery of drugs or therapeutic radio-metals into tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.